Jeffrey Siegel

10.7k citations

41 papers · 6.1k indexed · 2 hit papers · h-index 22

Immunology top 1%
Epidemiology top 1%
Infectious Diseases top 0.5%
Rheumatology top 0.5%
Surgery top 2%

Co-authors: M. Miles Braun Robert P. Wise William D. Schwieterman Sharon K. Gershon Joseph Keane John Kasznica Lawrence E. Samelson Evelyne T. Edwards
Topics: Immune Cell Function and Interaction (5 papers)Rheumatoid Arthritis Research and Therapies (5 papers)Glycosylation and Glycoproteins Research (4 papers)
Cited by: Rheumatology Immunology Infectious Diseases
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: United States United Kingdom Canada

In The Last Decade

Jeffrey Siegel

40 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

2001 2.7k citations Joseph Keane, Sharon K. Gershon et al. New England Journal of Medicine profile →
Demyelination occurring during anti-tumor necrosis factor ? therapy for inflammatory arthritides

2001 613 citations Niveditha Mohan, Evelyne T. Edwards et al. Arthritis & Rheumatism profile →

Peers

Countries citing papers authored by Jeffrey Siegel

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Siegel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Siegel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Siegel more than expected).

Fields of papers citing papers by Jeffrey Siegel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Siegel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Siegel. The network helps show where Jeffrey Siegel may publish in the future.

Co-authorship network of co-authors of Jeffrey Siegel

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Siegel. A scholar is included among the top collaborators of Jeffrey Siegel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Siegel. Jeffrey Siegel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Establishing a Public Resource for Acceptable Surrogate Endpoints to Support FDA Marketing Applications 2022 ·Frontiers in Medicine ·Abena S. Agyeman,Jeffrey Siegel,(unknown)	5
2	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial 2021 ·American Journal of Respiratory and Critical Care Medicine ·Dinesh Khanna,Celia J. F. Lin,Daniel E. Furst,Bridget K. Wagner,Mauro Zucchetto,Ganesh Raghu,Fernando J. Martínez,Jonathan Goldin,Jeffrey Siegel,Christopher P. Denton	72
3	Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis 2018 ·Annals of the Rheumatic Diseases ·Christopher P. Denton,Voon H Ong,Shiwen Xu,Haiyin Chen‐Harris,Zora Modrušan,Robert Lafyatis,Dinesh Khanna,Angelika Jahreis,Jeffrey Siegel,Thierry Sornasse	125
4	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate) 2017 ·Annals of the Rheumatic Diseases ·Dinesh Khanna,Christopher P. Denton,Celia J. F. Lin,Jacob M. van Laar,Tracy Frech,Marina Anderson,Murray Baron,Leland W.K. Chung,Gerhard Fierlbeck,Santhanam Lakshminarayanan,Yannick Allanore,Janet Pope,Gabriela Riemekasten,Virginia Steen,Ulf Müller‐Ladner,Helen Spotswood,L. Burke,Jeffrey Siegel,Angelika Jahreis,Daniel E. Furst	177
5	Successes Achieved and Challenges Ahead in Translating Biomarkers into Clinical Applications 2010 ·The AAPS Journal ·Greg H. Tesch,Shashi Amur,John T. Schousboe,Jeffrey Siegel,Lawrence J. Lesko,Jane P. F. Bai	17
6	Rhodopsin and the Others: A Historical Perspective on Structural Studies of G Protein-Coupled Receptors 2009 ·Current Pharmaceutical Design ·Stefano Costanzi,Jeffrey Siegel,Irina G. Tikhonova,Kenneth A. Jacobson	49
7	Trials in rheumatoid arthritis: choosing the right outcome measure when minimal disease is achievable 2008 ·Annals of the Rheumatic Diseases ·David T. Felson,Bin Zhang,Jeffrey Siegel	3
8	Guillain‐Barré and Miller Fisher syndromes occurring with tumor necrosis factor α antagonist therapy 2006 ·Arthritis & Rheumatism ·(unknown),Alan N. Baer,Hyon‐Jo Kwon,Elektra J. Papadopoulos,Jeffrey Siegel	145
9	Tuberculosis associated with therapy against tumor necrosis factor α 2005 ·Arthritis & Rheumatism ·Kevin Winthrop,Jeffrey Siegel,John Jereb,Zachary Taylor,Michael F. Iademarco	81
10	Use of the American College of Rheumatology N (ACR‐N) index of improvement in rheumatoid arthritis: Argument in favor 2005 ·Arthritis & Rheumatism ·Jeffrey Siegel,(unknown)	30
11	Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor 2004 ·Clinical Infectious Diseases ·(unknown),(unknown),Joel A. Block,Augustine Manadan,Jeffrey Siegel,M. Miles Braun	232
12	Infectious complications of biologic treatments of rheumatoid arthritis 2003 ·Current Opinion in Rheumatology ·Aparna Mohan,Timothy R. Coté,Jeffrey Siegel,M. Miles Braun	50
13	Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept 2002 ·Arthritis & Rheumatism ·Jong‐Hoon Lee,Nancy R. Slifman,Sharon K. Gershon,Evelyne T. Edwards,William D. Schwieterman,Jeffrey Siegel,Robert P. Wise,S Brown,John N. Udall,M. Miles Braun	337
14	Demyelination occurring during anti-tumor necrosis factor ? therapy for inflammatory arthritidesbreakdown → 2001 ·Arthritis & Rheumatism ·Niveditha Mohan,Evelyne T. Edwards,Thomas R. Cupps,Patrick J. Oliverio,Glenn D. Sandberg,Heidi Crayton,John R. Richert,Jeffrey Siegel	613
15	Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agentbreakdown → 2001 ·New England Journal of Medicine ·Joseph Keane,Sharon K. Gershon,Robert P. Wise,(unknown),John Kasznica,William D. Schwieterman,Jeffrey Siegel,M. Miles Braun	2706
16	Impaired Induction of the Apoptosis-Protective Protein Bcl-xL in Activated PBMC from Asymptomatic HIV-Infected Individuals 1997 ·Journal of Clinical Immunology ·Patrick J. Blair,Lawrence Boise,Stephen P. Perfetto,Bruce L. Levine,(unknown),Kenneth F. Wagner,Daniel C. St. Louis,Craig B. Thompson,Jeffrey Siegel,C H June	14
17	Measurement of CD69 induction in the assessment of immune function in asymptomatic HIV-infected individuals 1997 ·Cytometry ·Stephen P. Perfetto,Theresa E. Hickey,Patrick J. Blair,V C Maino,K Wagner,Sheng Zhou,Douglas L. Mayers,(unknown),Carl H. June,Jeffrey Siegel	24
18	Raf‐1 provides a dominant but not exclusive signal for the induction of CD69 expression on T cells 1995 ·European Journal of Immunology ·David Taylor,Jeffrey Siegel	49
19	Rapid activation of C-Raf-1 after stimulation of the T-cell receptor or the muscarinic receptor type 1 in resting T cells. 1993 ·The Journal of Immunology ·Jeffrey Siegel,Carl H. June,H Yamada,Ulf R. Rapp,Lawrence E. Samelson	35
20	Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. 1990 ·Proceedings of the National Academy of Sciences ·C H June,Mary C. Fletcher,J A Ledbetter,Gary L. Schieven,Jeffrey Siegel,A. F. Phillips,Lawrence E. Samelson	456

About Jeffrey Siegel

Jeffrey Siegel is a scholar working on Virology, Immunology and Rheumatology, having authored 41 papers that have together received 6.1k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (5 papers), Rheumatoid Arthritis Research and Therapies (5 papers) and Glycosylation and Glycoproteins Research (4 papers). The work is most often cited by research in Rheumatology (1.5k citations), Immunology (2.1k citations) and Infectious Diseases (1.6k citations). Jeffrey Siegel has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include M. Miles Braun, Robert P. Wise, William D. Schwieterman, Sharon K. Gershon, Joseph Keane, John Kasznica, Lawrence E. Samelson, Evelyne T. Edwards, Niveditha Mohan and Thomas R. Cupps. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact